Skip to main content

What is the difference between Ogivri and Herceptin?

Medically reviewed by Judith Stewart, BPharm. Last updated on May 16, 2024.

Official answer

by Drugs.com

Ogivri (trastuzumab-dkst) is a biosimilar to Herceptin (trastuzumab).

A biosimilar is a biological product that is FDA-approved and highly similar to a biologic already FDA-approved with no clinically meaningful differences in terms of safety and effectiveness from the reference product.

What Are Biosimilars? Top Facts You May Not Know

Ogivri and Herceptin are both used for the treatment of patients with HER2+ breast cancer or HER2-overexpressing metastatic stomach cancer (metastatic gastric or gastroesophageal junction adenocarcinoma).

Ogivri has not been approved as an interchangeable biosimilar, meaning the pharmacist cannot substitute Ogivri for Herceptin without consulting the prescriber.

Ogivri was the first approved biosimilar to Herceptin.

Herceptin (trastuzumab) Biosimilars

Read next

What are monoclonal antibodies?

Monoclonal antibodies (mAbs) are man-made proteins that mimic the natural antibodies produced by our immune systems. Monoclonal antibodies can be formulated into medicines to treat various types of illnesses, such as cancer, rheumatoid arthritis or psoriasis. Continue reading

What are biosimilar drugs and how do they compare to biologics?

A biosimilar is a biological product that is similar to a reference biologic (usually the originally approved product) and for which there are no clinically meaningful differences in terms of safety, purity, and potency. One example is Amjevita (adalimumab-atto), the first biosimilar approved for Humira (adalimumab) in 2016. Continue reading

How long can you stay on Herceptin and Perjeta?

If you are receiving Perjeta for treatment of HER2+ early breast cancer, you may continue treatments with Herceptin every 3 weeks for one year (18 cycles total). For the treatment of HER2+ metastatic breast cancer, you will receive Perjeta and Herceptin until the medicine no longer controls your breast cancer or you have side effects that require you to stop treatment. You may receive other treatments with these medications. Continue reading

Related medical questions

Drug information

Related support groups